Page last updated: 2024-10-27

fexofenadine and Inflammation

fexofenadine has been researched along with Inflammation in 3 studies

fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.

Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.

Research Excerpts

ExcerptRelevanceReference
"Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo."9.11Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005)
"Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments."5.31Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002)
"Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo."5.11Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005)
"Fexofenadine is a substrate of these transporters and it was previously shown that its clearance is reduced in the rat isolated perfused liver following treatment with E."1.36Pharmacokinetics of fexofenadine following LPS administration to rats. ( Davey, AK; Gerber, JP; Jaisue, S, 2010)
"Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments."1.31Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. ( Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jaisue, S1
Gerber, JP1
Davey, AK1
Gelfand, EW1
Cui, ZH1
Takeda, K1
Kanehiro, A1
Joetham, A1
Fardon, TC1
Lee, DK1
Hodge, MR1
Lipworth, BJ1

Trials

1 trial available for fexofenadine and Inflammation

ArticleYear
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:3

    Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Alb

2005

Other Studies

2 other studies available for fexofenadine and Inflammation

ArticleYear
Pharmacokinetics of fexofenadine following LPS administration to rats.
    Xenobiotica; the fate of foreign compounds in biological systems, 2010, Volume: 40, Issue:11

    Topics: Administration, Oral; Animals; Anti-Allergic Agents; Biological Availability; Inflammation; Injectio

2010
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
    The Journal of allergy and clinical immunology, 2002, Volume: 110, Issue:1

    Topics: Adoptive Transfer; Allergens; Animals; Anti-Allergic Agents; Bronchial Hyperreactivity; Bronchoalveo

2002